KR20090127867A - 인다졸 화합물 - Google Patents

인다졸 화합물 Download PDF

Info

Publication number
KR20090127867A
KR20090127867A KR1020097014013A KR20097014013A KR20090127867A KR 20090127867 A KR20090127867 A KR 20090127867A KR 1020097014013 A KR1020097014013 A KR 1020097014013A KR 20097014013 A KR20097014013 A KR 20097014013A KR 20090127867 A KR20090127867 A KR 20090127867A
Authority
KR
South Korea
Prior art keywords
independently
compound
alkyl
deleted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097014013A
Other languages
English (en)
Korean (ko)
Inventor
청-밍 썬
밍-리앵 쿠오
Original Assignee
네이셔널 치아오 텅 유니버시티
내셔널 타이완 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네이셔널 치아오 텅 유니버시티, 내셔널 타이완 유니버시티 filed Critical 네이셔널 치아오 텅 유니버시티
Publication of KR20090127867A publication Critical patent/KR20090127867A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097014013A 2006-12-05 2007-12-03 인다졸 화합물 Withdrawn KR20090127867A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87304106P 2006-12-05 2006-12-05
US60/873,041 2006-12-05

Publications (1)

Publication Number Publication Date
KR20090127867A true KR20090127867A (ko) 2009-12-14

Family

ID=39492604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097014013A Withdrawn KR20090127867A (ko) 2006-12-05 2007-12-03 인다졸 화합물

Country Status (9)

Country Link
US (1) US7825261B2 (enExample)
EP (1) EP2091329A4 (enExample)
JP (1) JP2010511721A (enExample)
KR (1) KR20090127867A (enExample)
CN (1) CN101616587A (enExample)
AU (1) AU2007329480A1 (enExample)
CA (1) CA2671543A1 (enExample)
TW (1) TWI433672B (enExample)
WO (1) WO2008070599A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
ES2574253T3 (es) 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CA2913085A1 (en) 2013-05-23 2014-11-27 Bernhard Lindenthal Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101713303B1 (ko) 2015-12-24 2017-03-07 강원대학교산학협력단 2ｈ-인다졸 유도체의 제조방법
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021067393A1 (en) * 2019-10-01 2021-04-08 Memorial Sloan Kettering Cancer Center SMALL MOLECULE INHIBITORS OF Id PROTEINS
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
CA2356638A1 (en) * 1998-12-23 2000-07-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
MXPA05010824A (es) * 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
BRPI0409888A (pt) * 2003-04-18 2006-05-23 Memory Pharm Corp derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
ATE519488T1 (de) * 2004-12-27 2011-08-15 Novartis Ag Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤

Also Published As

Publication number Publication date
JP2010511721A (ja) 2010-04-15
AU2007329480A1 (en) 2008-06-12
US20080132501A1 (en) 2008-06-05
US7825261B2 (en) 2010-11-02
WO2008070599A1 (en) 2008-06-12
CN101616587A (zh) 2009-12-30
EP2091329A1 (en) 2009-08-26
CA2671543A1 (en) 2008-06-12
TWI433672B (zh) 2014-04-11
EP2091329A4 (en) 2011-02-23
TW200836720A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
KR20090127867A (ko) 인다졸 화합물
AU721247B2 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP1020462B1 (en) Heterocyclic compounds and antitumor agent containing the same as active ingredient
US6294517B1 (en) Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5994294A (en) Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20040209902A1 (en) Aminoquinoline compounds
AU757558B2 (en) Imidazole derivatives as MDR modulators
PT2125776T (pt) Compostos espiro substituídos como inibidores da angiogénese
CN114716436A (zh) Kras g12c突变抑制剂及其用途
PT1389617E (pt) Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo
US20040259916A1 (en) Six membered amino-amide derivatives an angiogenisis inhibitors
JP2007520435A (ja) 抗癌剤としてのピリジノ［１，２−ａ］ピリミジン−４−オン化合物
KR20080006614A (ko) 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
CN103172577B (zh) 4-氨基喹唑啉及4-氨基喹啉类化合物及其用途
JP4828142B2 (ja) 新規な融合ピラゾリル化合物
US20050065161A1 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
CN116655599A (zh) 一类egfr别构抑制剂的合成及其用途
CN112094223B (zh) 一类脲基四氢咔唑类小分子有机化合物及用途
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
US20110082143A1 (en) Bicyclic Heteroaryl Compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)